However, recently, combinations targeting the same pathway (e.g. trametanib (MEK) inhibitor together with dabrafenib (BRAF inhibitor) in BRAF-mutant melanoma [8] or resistance pathways (combining PIK3CA and MEK inhibitors) [9] showed efficacy, either preclinically and/or in the clinic. The gene discussed is MAP2K7; the disease is melanoma.